 Ocular Therapeutix Inc NASDAQ: OCUL on Friday released limited data from its presentation on the ongoing Phase 1 trial evaluating OTX-TKI for wet age-related macular degeneration and other retinal diseases. Ocular presented the data at the Angiogenesis, Exudations, and Degeneration 2021 Meeting. 